names of glp-1 drugs glp 1 oral list List current and its analogs [36-39] Prescription Weight Loss Drugs: Types,
Description
In this subgroup, 27% of participants randomized to semaglutide de-escalated therapy versus 3% for placebo, and 36% no longer met RHTN criteria at study completion versus 21% in the placebo group
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial
![names of glp-1 drugs glp 1 oral list List current and its analogs [36-39] Prescription Weight Loss Drugs: Types,](https://niveshaay.com/wp-content/uploads/2025/08/GLP-1_Charts-01-1-1024x664.png)
[42] [43] Liraglutide was approved by the FDA in 2019, for treatment of children aged ten years of age or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved in 2000
![names of glp-1 drugs glp 1 oral list List current and its analogs [36-39] Prescription Weight Loss Drugs: Types,](https://www.nanalyze.com/app/uploads/2024/08/This-Drug-Will-Disrupt-Everything.-Is-Your-Portfolio-Ready_image-13-1024x575.png)
By improving metabolic regulation, moderating nutrient signaling, and reducing chronic inflammatory burden, these therapies may help alleviate physiological stress that contributes to age-related disease and functional decline
![names of glp-1 drugs glp 1 oral list List current and its analogs [36-39] Prescription Weight Loss Drugs: Types,](https://josephcarerx.com/wp-content/uploads/2025/04/glp-1-ig-mobile.jpg)
doi:10.1007/s40262-017-0528-2 23
![names of glp-1 drugs glp 1 oral list List current and its analogs [36-39] Prescription Weight Loss Drugs: Types,](https://images.ctfassets.net/4f3rgqwzdznj/2zOOXVnmS5ExpkOMLBGlOZ/9626d72ba81ecfb39b173a74b699ced2/23-02_Comparison_of_GLP-1_Agonist_Drugs.png)